Doctors and scientists at Massachusetts General Hospital and Hackensack University Medical Center will join teams at the National Cancer Institute and Washington University at St Louis in helping evaluate the cell therapy.
The treatment will be used to combat difficult relapsed or refractory ovarian cancer and malignant peritoneal mesothelioma, which affects the lining of the abdomen.
The new teams will administer MCY-M11 via the peritoneum and patients will receive what is called a preconditioning regimen, consisting of a chemotherapy called cyclophosphamide.
Preconditioning is a widely used strategy to increase the efficacy of CAR-T treatment or to reduce its side effects.
“The addition of preconditioning regime in a separate cohort also provides a comparator to the MCY-M11 used as a single agent and will progress independently from the ongoing evaluation of MCY-M11 in the existing phase I cohort, and which is anticipated to be completed during 2020,” said Emma Ulker, analyst at Proactive Research.
MaxCyte expanded the phase I clinical assessment after unveiling “encouraging preliminary results” from the study in May.
Preliminary clinical data from the earlier patient groups are expected sometime in the second half of this year.
“The trial expansion highlights the potential for enhancing the breadth of data, efficacy and pace of recruitment into the phase I study of the lead CARMA candidate,” said Proactive analyst Ulker.
“This is central to the strategic planning for the CARMA Cell Therapies subsidiary, which is on track to secure independent funding in 2020.”
The shares were up 4.5% in early afternoon trade at 350p, valuing the business at £262mln.
---Adds analyst comment, video, link to the latest MaxCyte research---